GlassScriptPhysician profile
Mark J Zalla
NPI 1356460018
$862.55
in general payments reported to CMS, 2019-2025
22 companies · $19.11 in 2025
The $19.11 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $108 · 2021: $140 · 2022: $290 · 2023: $105 · 2024: $94.22 · 2025: $19.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $218.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $166.54 | 2020-2022 | |
| Janssen Biotech, INC. | $122.03 | 2019-2023 | Remicade, Simponi, Stelara |
| Abbvie INC. | $64.61 | 2023-2024 | Skyrizi |
| Genentech USA, INC. | $58.47 | 2019-2022 | |
| Galderma Laboratories, L.P. | $42.47 | 2021-2022 | |
| Ucb, INC. | $40.00 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $39.30 | 2019-2022 | |
| Almirall LLC | $36.97 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $35.81 | 2022-2023 | Dupixent |
| Mimedx Group, INC. | $34.80 | 2024 | |
| Incyte Corporation | $32.63 | 2023 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.53 | 2020 | |
| Organogenesis INC. | $20.52 | 2024 | |
| Reprise Biomedical, INC. | $19.11 | 2025 | Miro3d |
| Lilly USA, LLC | $19.07 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $16.94 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.43 | 2021 | |
| Pfizer INC. | $14.19 | 2019 | |
| Genzyme Corporation | $13.72 | 2020 | |
| Kyowa Kirin, INC. | $13.47 | 2023 | Poteligeo |
| Leo Pharma INC. | $13.02 | 2019 | |
| Merck Sharp & Dohme LLC | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Zalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.